The IMPACT Accelerator Cycle 2 is in motion with Sponsor BARDA

Cycle 2 of the IMPACT Accelerator program is well underway as the ten selected startups work with representatives from the current Cycle sponsor, BARDA, to prepare for the pitch-off event on April 21st.

For Cycle 2, our sponsors’ Areas of Interest focused on developing digital health solutions to improve at-home care, early-disease detection devices, and host-based therapeutics. In January, we worked with BARDA to choose 10 highly innovative, early-stage medtech startups to join Cohort 2.

Continue reading

$200K Challenge is Back – Making an Impact In-Person this Year

Over the last two years, we have been unable to come together to celebrate the $200K Challenge, and the startups involved in it. Luckily, we were still able to work virtually with innovative entrepreneurs around the country to help advance their innovations.

We are beyond thrilled to announce that this year, the $200K Challenge Pitch-Off will take place in-person, at M2D2. As our first major hybrid event in two years, we are excited – and cautious. We will have precautions in place and will continue to monitor the current situation to ensure everyone’s safety – stay updated by checking our Challenge website and subscribing to the M2D2 email.

Continue reading

M2D2 Announces the first IMPACT Accelerator Program Cohort

10 startups have been selected to participate in the first cohort of the IMPACT Accelerator Program.

This week, M2D2 announced the finalists for its IMPACT Accelerator Program, a recently launched 12-week program designed to help early-stage companies advance their innovation. These 10 finalists will work closely with M2D2 and its network of experts, receiving 1-on-1 mentorship, education workshops, and access to lab equipment. After the 12-week program, the startups will be part of a public pitch event, where other life sciences startups and investors can learn more about their innovation. 

Continue reading

Stephen Tyrpak, Director of Clinical & Regulatory Affairs at Garwood Medical Devices, to Participate in Clinical Trial Program Sponsored by Johnson & Johnson Innovation – JLABS

Tyrpak will be a featured speaker and panelist as part of the UMass M2D2 Key Considerations & Best Practices” session on June 15.

BUFFALO, N.Y., June 11, 2021Stephen Tyrpak, director of clinical & regulatory affairs at Garwood Medical Devices, LLC, will be a featured speaker and panelist at a June 15 virtual event being coordinated by the Massachusetts Medical Device Center (M2D2) at UMass Lowell and sponsored by Johnson & Johnson Innovation – JLABS.

Tyrpak will share his expertise and insights regarding key considerations and best practices related to regulatory strategy in and out of the U.S., the importance of reimbursement considerations early on, and clinical study design and management for early-stage companies seeking regulatory approval. He is one of five participants in the third and final program in the M2D2 Clinical Trial Series.

Continue reading